Pharmacies that make customized medications are asking the federal Food and Drug Administration to protect their right to create homemade versions of Wegovy, Zepbound and other GLP-1 agonist weight-loss drugs.
The Alliance for Pharmacy Compounding is asking patients to use an online letter-writing system to tell the FDA that they want the agency to continue to let compounding pharmacies compound the two GLP-1 agonists now commercially available, semaglutide and tirzepatide.
The pharmacies are objecting to drugmakers' argument that compounded versions of the GLP-1 agonists are dangerous.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Allison Bell
Allison Bell, a senior reporter at ThinkAdvisor and BenefitsPRO, previously was an associate editor at National Underwriter Life & Health. She has a bachelor's degree in economics from Washington University in St. Louis and a master's degree in journalism from the Medill School of Journalism at Northwestern University. She can be reached through X at @Think_Allison.
